ClinicalTrials.gg
CompletedNCT06820710I-COUNTUpdated Apr 8, 2026

Multidomain Interventions for Elderly Individuals in Residential Structures

An interventional study of Physical activity and Cognitive stimulation in Aging, Age-Related Cognitive Decline and Sarcopenia, sponsored by Istituto di Neuroscienze Consiglio Nazionale delle Ricerche. Completed at 2 sites in Italy. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2026-04-08.

Sponsored by Istituto di Neuroscienze Consiglio Nazionale delle Ricerche · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
70 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 70 studies in Sarcopenia with a site in Italy — 29 open to participants now, 32 under way, 1 of them phase 3. Sarcopenia · Italy.

Enrollment
21st of 39
90 · median 100
Started
2025
with 5 others
No phase
35 of 70
13 open now
Registered
51st of 70
by date
Lead sponsor
2 of 70
Istituto di Neuroscienze Consiglio Nazionale delle Ricerche

Among the 70 studies in Sarcopenia with a site in Italy, this one is the 21st largest by enrollment of the 39 interventional ones that give a count, is one of 6 that started in 2025, is one of 35 with no phase, and was the 51st registered.

Sarcopenia

1,334 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.

Browse Sarcopenia studies →

Open to participants now

29 of the 70 studies in Sarcopenia with a site in Italy are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 246 Sarcopenia studies recruiting now, 155 (63%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 62 take healthy volunteers.

This study: 70 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies in Sarcopenia with a site in Italy, or all of them as a file.
02

Study summary

The "Multidomain Interventions to improve the COgnitive and fUNctional well-being of elderly individuals in residential sTructures" (I-COUNT) study aims to test the feasibility and the effectiveness of a multidisciplinary intervention among elderly individuals living in long term care facilities (LTCFs). The intervention will include selected physical and cognitive training activities administered and monitored by new technologies, a dietary intervention including also functional foods, and the administration of vaccines according to the National plan. The multidomain intervention will last 6 months and will be compared with the standard care adopted in the same LTCFs.

Read the detailed description

I-COUNT is a randomized controlled trial that will be conducted among residents in two residential facilities in Italy. Sixty participants will be enrolled in each residential facility (30 control group, 30 intervention group).

During the first phase of the study, eligible residents of the participating LTCFs will be enrolled according to the following inclusion and exclusion criteria. Baseline evaluations will be based on a geriatric multidimensional assessment including body composition assessment, physical performance assessment, Mediterranean diet adherence assessment, psychological and neuropsychological evaluations. Blood, plasma, stool and urine samples will also be collected.

In phase two, which will last 6 months, participants in the intervention group will undergo the planned interventions, while controls will be asked to continue with their usual activities. The physical activity will consist of three 40-minutes sessions per week, with personalized exercises prescribed by a physiotherapist and performed in small groups, under supervision. The cognitive training will be based on the computer program Remote stimulation for Cognitive Decline (RECODE), developed by the Department of General Psychology, University of the Padua, with two sessions per week. The intervention group will also receive functional foods (sourdough bread enriched with a vegetable matrix rich in polyphenols (olive leaves) and vegetables enriched with probiotics (artichokes)).

In phase 3, participants will be reassessed at 3 months (gut microbiota only), and 6 and 9 months after the start of the intervention (selected biomarkers, nutritional and anthropometric status, psychological health, physical performance tests, cognitive function, acceptability of the technological monitoring and interventions).

03

Conditions studied

  • Aging
  • Age-Related Cognitive Decline
  • Sarcopenia
  • Long Term Care Facility
  • Cognitive Training
  • Physical Exercise
  • Functional Food
  • Nutritional Intervention
  • Vaccinations

Keywords

  • aging
  • long term care facilities
  • multidimensional interventions
  • cognitive training
  • physical exercise
  • nutritional intervention
  • functional foods
  • vaccinations
04

Who can participate

Ages eligible
70 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age ≥70 years;
  • resident in the identified LTCFs for at least 6 months;
  • able to communicate and collaborate with the research team;
  • -MMSE ≥18.

Exclusion criteria

Exclusion Criteria:

  • estimated length of stay in the LTCFs\<6 months;
  • estimated \<6 months;
  • previous gastrectomy or colectomy;
  • presence of a nasogastric tube or percutaneous endoscopic gastrostomy (PEG);
  • presence of dysphagia;
  • inability to undergo psychometric tests for any reason;
  • history of psychiatric illness according to clinical anamnesis;
  • inability to walk.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    Multidomain Intervention group

    The 6-month intervention will include supervised physical exercises (each session will last 40 minutes, three times a week, with accelerometers and smartwatches to monitor the physical activity performed), and cognitive stimulation (delivered by neuropsychologists twice a week for 30 minutes, in small groups). Participants in the intervention group will be advised to follow a Mediterranean diet, will receive functional foods (sourdough bread fortified with vegetable matrix rich in polyphenols and probiotic artichokes), and will be offered to receive appropriate vaccinations according to the national vaccination calendar.

    Other: Physical activity · Other: Cognitive stimulation · Other: Nutritional Intervention · Other: Vaccinations

  • No intervention
    Control group (usual activities)

    Subjects in the control group will receive general information on healthy lifestyles and health, including risk factors.

Interventions

  • OtherPhysical activity

    Appropriate exercises for supervised small group sessions will be prescribed by a physiotherapist or expert in exercise science. Each session will last approximately 40 minutes, three times a week, and will be based on the international guidelines for physical exercise in the elderly population, and the VIVIFRAIL Multicomponent Physical Exercise Program to Prevent Frailty and the Risk of Falls. Accelerometers and other wearable sensors (smartwatches) will be used to monitor the physical activity performed.

  • OtherCognitive stimulation

    Cognitive stimulation will be delivered by expert neuropsychologists twice a week (48 sessions in total) for approximately 30 minutes. Residents will be divided into small groups (3-5 people) of similar cognitive level, and the intervention will be delivered using a computerized tool (REmote stimulation for COgnitive DEcline (RECODE) developed by researchers at the University of Padova with the aim of stimulating different domains (i.e., attention, working memory, visual memory, language, orientation and executive functions) through exercises of increasing difficulty.

  • OtherNutritional Intervention

    Participants in the intervention group will be advised to follow a Mediterranean diet and will also receive functional foods; in particular, they will be offered 80 g/day of sourdough bread fortified with vegetable matrix rich in polyphenols (e.g., olive leaves) and 100 g/day of probiotic artichokes on alternate days.

  • OtherVaccinations

    Participants in the intervention group will be offered to receive appropriate vaccinations according to the national vaccination calendar. Vaccine doses will be provided by the Department of Preventive Medicine, Vaccine Office, National Health Service, on prescription from the general practitioners.

06

What researchers measure

Primary outcomes

  1. Effect of the multidomain intervention on the gut microbiota composition

    Changes in gut microbiota biodiversity measured as species richness (number of different taxa identified in each sample) in the intervention group compared to control group

    Time frame: Baseline and 3 months after the start of the intervention

  2. Effect of the multidomain intervention on the gut microbiota composition

    Changes in gut microbiota in term of the most represented bacterial taxa (such as Faecalibacterium prausnitzii, Akkermansia muciniphila, Bifidobacterium spp, Lactobacillus spp; measured as average relative abundance) in the intervention group compared to control group

    Time frame: Baseline and 3 months after the start of the intervention

  3. Effect of the multidomain intervention on the gut microbiota composition

    Changes in gut microbiota in terms of gene or transcript counts (measured as counts) in the intervention group compared to control group

    Time frame: Baseline and 3 months after the start of the intervention

Secondary outcomes

  1. Feasibility of the multidomain intervention

    Number of drop out (number) in the intervention group compared to control group

    Time frame: At the end of the intervention (6 months after the start)

  2. Effect of the multidomain intervention on the gut microbiota composition

    Changes in gut microbiota biodiversity measured as species richness (number of different taxa identified in each sample) in the intervention group compared to control group

    Time frame: Baseline, 6 and 9 months after the start of the intervention

  3. Effect of the multidomain intervention on the gut microbiota composition

    Changes in gut microbiota in terms of gene or transcript counts (measured as counts) in the intervention group compared to control group

    Time frame: Baseline, 6 and 9 months after the start of the intervention

  4. Effect of the multidomain intervention on the gut microbiota composition

    Changes in gut microbiota in term of the most represented bacterial taxa (such as Faecalibacterium prausnitzii, Akkermansia muciniphila, Bifidobacterium spp, Lactobacillus spp; measured as average relative abundance) in the intervention group compared to control group

    Time frame: Baseline, 6 and 9 months after the start of the intervention

  5. Effect of the multidomain intervention on specific biomarkers

    Changes in cholesterol (measured in mg/dl) in the intervention group compared to control group

    Time frame: Baseline, 6 and 9 months after the start of the intervention

  6. Effect of the multidomain intervention on specific biomarkers

    Changes in triglycerides (measured in mg/dL) in the intervention group compared to control group

    Time frame: Baseline, 6 and 9 months after the start of the intervention

  7. Effect of the multidomain intervention on specific biomarkers

    Changes in blood glucose (measured in mg/dL) in the intervention group compared to control group

    Time frame: Baseline, 6 and 9 months after the start of the intervention

  8. Effect of the multidomain intervention on specific biomarkers

    Changes in vitamin D (measured in nmol/L) in the intervention group compared to control group

    Time frame: Baseline, 6 and 9 months after the start of the intervention

  9. Effect of the multidomain intervention on specific biomarkers

    Changes in transferrin (measured in mg/dL) in the intervention group compared to control group

    Time frame: Baseline, 6 and 9 months after the start of the intervention

  10. Effect of the multidomain intervention on specific biomarkers

    Changes in albumin (measured in g/dL) in the intervention group compared to control group

    Time frame: Baseline, 6 and 9 months after the start of the intervention

  11. Effect of the multidomain intervention on specific biomarkers

    Changes in FT3 (measured in pg/mL) in the intervention group compared to control group

    Time frame: Baseline, 6 and 9 months after the start of the intervention

  12. Effect of the multidomain intervention on specific biomarkers

    Changes in FT4 (measured in ng/dL) in the intervention group compared to control group

    Time frame: Baseline, 6 and 9 months after the start of the intervention

  13. Effect of the multidomain intervention on specific biomarkers of aging

    Changes in IL-6 (measured in pg/mL) in the intervention group compared to control group

    Time frame: Baseline, 6 and 9 months after the start of the intervention

  14. Effect of the multidomain intervention on specific biomarkers of aging

    Changes in BDNF (measured in ng/ml) in the intervention group compared to control group

    Time frame: Baseline, 6 and 9 months after the start of the intervention

  15. Effect of the multidomain intervention on specific biomarkers of aging

    Changes in s-RAGE (measured in pg/mL) in the intervention group compared to control group

    Time frame: Baseline, 6 and 9 months after the start of the intervention

  16. Effect of the multidomain intervention on specific biomarkers of aging

    Changes in irisin (measured in ng/ml) in the intervention group compared to control group

    Time frame: Baseline, 6 and 9 months after the start of the intervention

  17. Effect of the multidomain intervention on specific biomarkers of aging

    Changes in IGF1 (measured in ng/mL) in the intervention group compared to control group

    Time frame: Baseline, 6 and 9 months after the start of the intervention

  18. Effect of the multidomain intervention on specific biomarkers of aging

    Changes in ghrelin (measured in pg/mL) in the intervention group compared to control group

    Time frame: Baseline, 6 and 9 months after the start of the intervention

  19. Effect of the multidomain intervention on the nutritional status

    Changes in Mini Nutritional Assessment (MNA, score 0-30, a higher score indicates a better outcome) in the intervention group compared to control group

    Time frame: Baseline, 6 and 9 months after the start of the intervention

  20. Effect of the multidomain intervention on anthropometric status and body composition

    Changes in body mass index (BMI, with weight measured in kg and height measured in m combined to report BMI in kg/m\^2) in the intervention group compared to control group

    Time frame: Baseline, 6 and 9 months after the start of the intervention

  21. Effect of the multidomain intervention on anthropometric status and body composition

    Changes in waist circumference (measured in cm) in the intervention group compared to control group

    Time frame: Baseline, 6 and 9 months after the start of the intervention

  22. Effect of the multidomain intervention on anthropometric status and body composition

    Changes in calf circumference (measured in cm) in the intervention group compared to control group

    Time frame: Baseline, 6 and 9 months after the start of the intervention

  23. Effect of the multidomain intervention on anthropometric status and body composition

    Changes in mid-upper arm circumference (measured in cm) in the intervention group compared to control group

    Time frame: Baseline, 6 and 9 months after the start of the intervention

  24. Effect of the multidomain intervention on upper limb strength

    Changes in upper limb strength evaluated with electronic hand dynamometers (measured in kg) in the intervention group compared to control group

    Time frame: Baseline, 6 and 9 months after the start of the intervention

  25. Effect of the multidomain intervention on general and domain-specific cognitive functioning

    Changes in the Addenbrooke's Cognitive Examination (ACE-R, minimum 0, maximum 10, a higher score indicate a better outcome) in the intervention group compared to control group

    Time frame: Baseline, 6 and 9 months after the start of the intervention

  26. Effect of the multidomain intervention on physical performance

    Changes in the Short Physical Performance Battery (SPPB, minimum 0, maximum 12, a higher score indicates a better outcome) in the intervention group compared to control group

    Time frame: Baseline, 6 and 9 months after the start of the intervention

  27. Effect of the multidomain intervention on psychological health

    Changes in the Geriatric Depression Scale (GDS, minimum score 0, maximum score 30, a higher score indicates a worse outcome) in the intervention group compared to control group

    Time frame: Baseline, 6 and 9 months after the start of the intervention

  28. Effect of the multidomain intervention on psychological health

    Changes in the Perceived Stress Scale (PSS, minimum score 0, maximum score 40, a higher score indicates worse outcome) in the intervention group compared to control group

    Time frame: Baseline, 6 and 9 months after the start of the intervention

  29. Effect of the multidomain intervention on psychological health

    Changes in the Depression Anxiety Stress Scale (DASS-21, minimum score 0, maximum score 63, a higher score indicates worse outcome) in the intervention group compared to control group

    Time frame: Baseline, 6 and 9 months after the start of the intervention

  30. Effect of the multidomain intervention on quality of life

    Changes in the World Health Organization Quality of Life Scale (WHOQOL-BREF Physical Health, minimum score 0, maximum score 100, a higher score represents a better outcome) in the intervention group compared to control group

    Time frame: Baseline, 6 and 9 months after the start of the intervention

  31. Effect of the multidomain intervention on quality of life

    Changes in the World Health Organization Quality of Life Scale (WHOQOL-BREF Psychological Health, minimum score 0, maximum score 100, a higher score represents a better outcome) in the intervention group compared to control group

    Time frame: Baseline, 6 and 9 months after the start of the intervention

  32. Effect of the multidomain intervention on quality of life

    Changes in the World Health Organization Quality of Life Scale (WHOQOL-BREF Social Relationships, minimum score 0, maximum score 100, a higher score represents a better outcome) in the intervention group compared to control group

    Time frame: Baseline, 6 and 9 months after the start of the intervention

  33. Effect of the multidomain intervention on quality of life

    Changes in the World Health Organization Quality of Life Scale (WHOQOL-BREF Environment, minimum score 0, maximum score 100, a higher score represents a better outcome) in the intervention group compared to control group

    Time frame: Baseline, 6 and 9 months after the start of the intervention

  34. Effect of the multidomain intervention on quality of life

    Changes in the World Health Organization Quality of Life Scale (WHOQOL-BREF Quality of Life, minimum score 0, maximum score 5, a higher score represents a better outcome) in the intervention group compared to control group

    Time frame: Baseline, 6 and 9 months after the start of the intervention

  35. Effect of the multidomain intervention on quality of life

    Changes in the World Health Organization Quality of Life Scale (WHOQOL-BREF Health Satisfaction, minimum score 0, maximum score 5, a higher score represents a better outcome) in the intervention group compared to control group

    Time frame: Baseline, 6 and 9 months after the start of the intervention

  36. Effect of the multidomain intervention on sleep quality

    Changes in the Pittsburgh Sleep Quality Index (PSQI, minimum score 0, maximum score 21, a higher score indicates a worse outcome) in the intervention group compared to control group

    Time frame: Baseline, 6 and 9 months after the start of the intervention

  37. Effect of the multidomain intervention on the number of hospitalization

    Incidence (number) of hospitalizations during follow-up in the intervention group compared to control group

    Time frame: 6 and 9 months after the start of the intervention

  38. Effect of the multidomain intervention on the number of falls

    Incidence (number) of falls during follow-up in the intervention group compared to control group

    Time frame: 6 and 9 months after the start of the intervention

07

Study locations

2 sites
  • RSA Cremona Solidale
    Cremona, Italy 26100, Italy
  • AltaVita IRA
    Padova, Italy 35137, Italy
08

References and documents

Publications

  • Romeo Z, Macchia E, Ceolin C, Devita M, Morandi A, Noale M, Maggi S; I-COUNT Study Group. Feasibility and Potential Effects of Multidomain Interventions to Improve the Cognitive and Functional Well-Being of Elderly Individuals in Residential Structures: The I-COUNT Pilot Study Protocol. Healthcare (Basel). 2025 Aug 14;13(16):1999. doi: 10.3390/healthcare13161999. PubMed 40868616 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2025 to primary completion in Dec 2025, 10 months.

Of 497 non-industry interventional studies with no phase under Sarcopenia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 34. This study's 10 months is below that.

Counting every sponsor, half of 509 studies reached it within 18 months; a quarter within 8 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2025
First posted
Feb 11, 2025
StartActual
Feb 3, 2025
Primary completionActual
Dec 31, 2025
CompletionActual
Dec 31, 2025
Last update
Apr 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06820710
Lead sponsor
Istituto di Neuroscienze Consiglio Nazionale delle Ricerche
Responsible party
Sponsor
First posted
Feb 11, 2025
Start date
Feb 3, 2025
Primary completion
Dec 31, 2025
Completion
Dec 31, 2025
Last update
Apr 8, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion